Two angiotensin II analogues, i.e., 1-sarcosine, 8-isoleucine angiotensin II (Sari, Ile-AII) and 1-sarcosine, 8-alanine angiotensin II (Sari, Ala8-AII), are now available in the clinical study.
The specific competitive inhibitor of angiotensin II, angiotensin II analogue (AIIA), is a useful tool for understanding a role of renin-angiotensin-aldosterone system in the physiological and pathophysiological conditions (Davis et al., 1974 ; Haber, 1976) .
At present two AIIA's are clinically available:
1-sarcosine, 8-isoleucine angiotensin II have been used in Japan (Ogihara et al., 1974) , 1-sarcosine, 8-alanim angiotensin II in western areas (Brunner et al., 1973; Streeten et al., 1976) . From the aspect of clinical application of them, it is interesting to compare the pharmacological actions of these two AIIA's. Furthermore, this structural analogue seems to be useful for the assessment of angiotensin II and angiotensin II-receptor interaction (Williams et al., 1974; Hollenberg et al., 1976) . In this study we compared the effects of these two AIIA's in normal subjects on three sodium balances and also in hypertensive patients with various causes on sodium depletion.
Materials and Methods
Study in normal subjects Subjects studied were five male volunteers aged 25 to 35 years. The following experiments were made in three different sodium balances, i.e., i) normal sodium state; unrestricted diet, ii) high sodium state; regular diet supplemented with 6g/day of sodium chloride, and iii) low sodium state; sodiumfree diet with 40 mg of furosemide given orally on the first day. Experiments were done on the 3rd and 4th day in each sodium state. Urinary sodium excretion (UNaV), plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were monitored each day. Experiment 1: Sar1, Ile8-AII and Sari, Ala8-AII were infused at a graded rate from 120 to 2,400ng/kg/min, respectively.
Each dose was infused for 10 min. Experiment 2: After assessing the rise in mean blood pressure at 30mmHg above the basal level by angiotensin II infusion, both analogues were then superimposed at the same rate as in Experiment 1. Experiment 3: Either Sari, Ile8-AII or Sari, Ala'-AII at a rate of 600ng/kg/min, and AII at a rate of 20ng/kg/min were infused for 30min. Before and at the end of the infusion PRA, PAC and onehour creatinine clearance were measured.
The effects of these compounds on various parameters were expressed as percent changes following them.
Study in hypertensive patients Twenty hypertensive patients with various etiologies, essential hypertension:
11, renovascular hypertension:
3, renoparenchymal hypertension: 3, primary aldosteronism: 3, were studied. All medications were discontinued for at least 2 weeks before the examination except in 3 patients with primary aldosteronism who were on 200mg/day of spironolactone.
On the 4th day after a low sodium diet coupled with 80 mg/day of furosemide for 3 days, Sari, Ile8-AII and Sari, Ala8-AII were infused into each patient for 30 min at a rate of 600ng/kg/min and 1,800ng/kg/min, respectively. These infusion rates were based on the finding in experiment 2 that the antagonistic effect of Sari, Ile8-AII was three times more than that of Sari, Ala8-AII in normal subjects.
Both Sari, Ile8-AII and Sari, Ala8-AII were synthetized by Dr. Sakakibara, Peptide Institute, Protein Research Foundation, Osaka, Japan and were processed in injectable forms by Dai-ichi Parmaceutical Co. Ltd.(Tokyo).
Synthetic angiotensin II (Hypertensin, Ciba) and AIIA were diluted with normal saline and infused intravenously with a Harvard infusion pump or a VolumetR (Sigma Motor Co.). Blood pressure was measured every 5 min automatically by Non-Stetho 7R (Parama Co. Ltd., Tokyo). The mean blood pressure was calculated as the diastolic pressure plus one third of pulse pressure. The control blood pressure was taken as the average of at least 5 stable readings before starting the infusion.
PRA and PAC were measured by radioimmunoassay using a commercial kit. The evaluation of statistical probability was done by the analysis of variance (Campbell, 1974) Discussion Both AIIA's, i.e., Sari, Ile8-AII and Sari, Ala8-AII, had an agonistic pressor action in normal subjects.
The pressor action of Fig.3 . Effects of two angiotensin II analogues on blood pressure, PRA, PAC, and creatinine clearance in normal subjects on regular diet. Sari, was greater than that of Sar1, Ala8-AII in all sodium balances. The pressor activity of both AIIA's varied with different sodium balances, being minimized by sodium depletion.
The antagonistic effect of both AIIA's was also affected by the variations in sodium balances, which was greatest in the low sodium state. These AIIA's had an agonistic effect on AII receptors other than vascular beds, i.e., renin release, aldosterone secretion and renal vasculature, in normal subjects on regular sodium intake. The extent of the agonistic activity by either AIIA on each AII receptor was different, suggesting that the sensitivity to AIIA of each AII receptor might differ.
Furthermore the agonistic effect on peripheral vascular beds was greater in Sari, Ile8-AII than Sar1, Ala8-AII, but the effect on aldosterone secretion, renin release and renal vasculature was not different between these two AIIA's. These results suggest that AII and AII-receptor interaction on various All targets might be heterogeneous.
AIIA has been widely used for evaluating a renin dependency in hypertensive patients. This AIIA possesses an agonistic effect due to its intrinsic activity as well as a specifically, competitively, antagonistic effect due to AII, and this agonistic pressor action is undesirable because this compound is given to the patients with high blood pressure. So an agent not only potent in antagonistic action but also devoid of agonistic effect is required from the clinical aspect. Case et al.(1976) reported that the infusion of Sar1, Ala8-AII showed a pressor response in about 50% of hypertensive patients they studied. In our study in which we used Sar1, Ile8-AII we observed a pressor response, particularly, in patients with low renin values such as primary aldosteronism or low-renin essential hypertension (Ogihara et al., 1974) . At present we have few reports in which the effect of these two clinically available AIIA's is compared. Bravo et al. (1976) observed that Sar1, had a more agonistic pressor action than Sar1, Ala8-AII in the comparative study of Sar1, Ile8-AII and Sar1, Thr8-AII in dogs and they concluded that Sar1, Thr8-AII was the most ideal agent for the clinical purpose, because it had the least pressor activity.
In the present comparative study in normal subjects we obtained the same findings as observed by Bravo et al.(1976) The influence of the variations in sodium balance on the agonistic or antagonistic effect of both AIIA's is similar among them, i.e., reduction of agonistic action or potentiation of antagonistic effect by sodium depletion.
The circulating level of AII modifies the sensitivity of the vascular AII receptors to AII (Kaplan and Silah, 1964) . Recent studies suggested that the variations in sodium balance changed the afffinity of vascular AII receptors for AII (Brunner et al., 1972) and the number of total vascular AII receptors (Devynck and Meyer, 1976) , and that these changes were modified by the circulating AII level (Deheneffe et al., 1976) and, possibly, the local level of AII in the vascular wall (Swales et al., 1975) affected by various sodium balances.
These two AIIA's also had an ago- nistic effect on adrenal glomerulosa, renal vasculature and juxtaglomerular apparatus, but the intensity of this action of both AIIA's on each parameter was not different. Beckerhoff et al.(1975) infused the subpressor dose of Sari, Ile8-AII and Sari, Ala8-AII into dogs and observed that Sari, Ile8-AII caused an increase of plasma aldosterone, but Sari, Ala8-AII had no steroidogenic activity, and suggested that AII receptors on vascular beds and adrenal glomerulosa were different. In our present study there was np difference in steroidogenesis between both AIIA's, however there existed a dissociation in the agonistic action of both AIIA's on peripheral vascular beds and adrenal glomerulosa. This finding may be explained by the functional difference of AII receptors in these AII targets. In vitro Williams et al. (1974) observed by using two different AIIA's i.e., Sari, Ala8-AII and Phe4, Tyr8-AII, that Sari, Ala8-AII had an agonistic effect on neither aortic strip nor adrenal cortex, whereas Phe4, Thr8-AII showed the stimmulating action of aortic strip although aldosterone secretion was unaffected by this AIIA, and they suggested by this dissociated finding that AII receptors were different in these two systems. Hollenberg et al.(1976) demonstrated that the attitude of blood pressure, renin and aldosterone secretion and renal vasculature to the graded-dose infusion of Sari, Ala8-AII was different in these systems, which implicated the difference of AII and AII receptor interaction at various AII targets.
In contrast, Johnson and Davis (1973) suggested that AII exerted its effect at a similar receptor site in vascular beds and adrenal cortex on the basis of the Sarl, Ala8-AII inhibited both vasoconstriction and steroidogenesis of exogeneous AII in dogs. However, Bravo et al.(1975) argued against this view because in a small dose Sari, Ile8-AII blocked the vasopressor action of AII, but it showed a very weak inhibition against aldosterone secretion by AII. These inconsistent observations may be explained by the differences of the species and experimental conditions used. Further investigations are necessary to confirm whether AII and AII receptor interaction in various AII targets is heterogeneous or homogeneous.
Sodium depletion minimizes the agonistic action and potentiates the antagonistic effect of both AIIA's.
The response of blood pressure to either AIIA in hypertensive patients with various causes on sodium depletion showed a good correlation between these two AIIA's.
So far evaluating the involvement of renin-angiotensin system in hypertension, the pretreatment of sodium depletion is necessary and both AIIA's are equally useful when salt depleted. Recently, Anderson et al.(1977) reported that blood pressure reduction to Sarl, Ala8-AII (Saralasin) was seen in 14 out of 34 hypertensive patients, most of low-renin essential hypertension during 4 or 5 weeks' diuretic therapy with hydrochlorothiazide, 50 to 100mg/day, or spironolactone, 100 to 400mg/day. This means excessive sodium depletion is not adequate for determination of renin dependency in hypertension. From our experience in a series of studies of hypertensive patients, a sodium-restricted diet (NaCl 5g/ day) coupled with 80mg of furosemide p.o. for 3 days is found to give a most desirable condition for this AIIA test to differentiate renin-dependent hypertension from lowreninemic hypertension (Ogihara et al., 1978) .
